

# SUPPLEMENT

## **Mortality Benefits of Antibiotic Computerised Decision Support System:**

### **Modifying Effects of Age**

**Angela LP Chow, PhD<sup>1,2</sup>, David C Lye, FRACP<sup>3,4</sup>, Onyebuchi A Arah, PhD<sup>2,5</sup>**

<sup>1</sup> Department of Clinical Epidemiology, Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore

<sup>2</sup> Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, United States

<sup>3</sup> Department of Infectious Diseases, Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore

<sup>4</sup> Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>5</sup> Center for Health Policy Research, University of California, Los Angeles (UCLA), Los Angeles, United States

**Supplementary Table S1. Empiric Antibiotics Recommended by Computerised Decision Support System, by Commonly Diagnosed Infection**

<b>Diagnosed infection</b>	<b>Recommended antibiotics for empiric therapy</b>
Community-acquired pneumonia	Amoxicillin-clavulanate, Clarithromycin
Severe community-acquired pneumonia	Penicillin, Ceftazidime, Azithromycin
Healthcare-associated pneumonia	Piperacillin-tazobactam, Vancomycin
Acute cholecystitis/cholangitis/ gallbladder empyema	Amoxicillin-clavulanate, Gentamicin
Liver abscess	Amoxicillin-clavulanate
Pyelonephritis/ perinephric abscess	Cefazolin, Gentamicin
Cystitis	Co-trimoxazole
Sepsis	Cloxacillin, Ceftazidime, Clindamycin